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Abstract
RORγt regulates TH17 differentiation, thymic T cell development and lymph node genesis. 
Although elimination of RORγt prevents TH17-mediated experimental autoimmune 
encephalomyelitis (EAE), it also disrupts thymocyte development, which could lead to lethal 
thymic lymphoma. Here we identified two amino acid mutations in RORγt (RORγtM) that 
preferentially disrupted TH17 differentiation but not thymocyte development. Mice expressing 
RORγtM were resistant to EAE associated with defective TH17 differentiation, but maintained 
normal thymocyte development and lymph node genesis, except for Peyer’s patches. RORγtM 
showed reduced ubiquitination at K69 that is selectively required for TH17 differentiation but not 
T cell development. This study will inform the development of treatments that selectively target 
TH17-mediated autoimmunity, but do not affect thymocyte development and induce lymphoma.
The transcription factor RORγt, encoded by the gene rorc2, instructs the differentiation of T 
helper 17 (TH17) cells. Activation of naïve T cells in the presence of TGF-β and interleukin 
6 (IL-6) is sufficient to up-regulate RORγt and induce differentiation into TH17 cells 1. 
TH17 cells produce the effector cytokines including IL-17 to mediate the pathological 
inflammation responsible for autoimmunity such as psoriasis and multiple sclerosis 2, 3, 4. In 
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addition, during thymocyte development, RORγt is up-regulated at the CD4+CD8+ (DP) 
stage to enhance their survival by up-regulating anti-apoptotic Bcl-xL5. RORγt−/− mice 
develop lethal thymic lymphomas likely resulting from abnormal thymocyte development 6. 
RORγt−/− mice also lack all lymph nodes, including gut-associated mesenteric lymph nodes 
and Peyer’s patches 5, 7, due to a requirement of RORγt for the development of lymphoid 
tissue inducer (LTi) cells, the progenitors for lymph node genesis 5, 8, 9. The mechanisms 
that distinguish the functions of RORγt in TH17 differentiation in the peripheral immune 
system and thymocyte development in the central immune system remain unknown. 
Dissecting these functions is critical for understanding how one central transcription factor 
regulates distinct differentiation processes in the peripheral and central immune systems. 
Given the essential function of RORγt in TH17 cells, RORγt inhibitors have been developed 
for treatment of TH17-dependent autoimmunity 10, 11, 12, 13, 14. Such inhibitors are also 
expected to interfere with RORγt function in thymocytes and thus impair T cell 
development, which could eventually lead to the development of lymphoma 6. Development 
of novel RORγt-based treatments that specifically target TH17-mediated autoimmunity is as 
such of high order 6.
RORγt is a steroid nuclear receptor that consists of three domains 15, 16: a conserved DNA-
binding domain with two zinc finger motifs responsible for DNA-binding; a conserved 
ligand-binding domain with a C-terminal AF2 motif responsible for recruiting steroid 
receptor co-activator (SRC) to stimulate gene expression 17, 18; and a hinge domain between 
the DNA- and ligand-binding domains. Upon ligand binding, RORγt recruits SRC and binds 
to target DNA to regulate target gene expression. To date, no function has been assigned to 
the RORγt hinge domain, which is generally believed to serve as a flexible linker region 
between the conserved and functionally important DNA-binding and ligand-binding 
domains. However, the observation that the hinge domain is not conserved between three 
members of the ROR family 19, suggests a potentially unique function.
By mutagenesis, we identified a mutant form of RORγt, which contains two amino acid 
mutations within the non-conserved hinge region of RORγt (called RORγtM in this 
manuscript) that specifically disrupted RORγt function in TH17 differentiation, but not 
thymocyte development. Mice expressing RORγtM in the endogenous RORγt locus (called 
RORγtM/M mice here) lacked TH17 differentiation, but had normal overall T cell 
development and developed most lymph nodes, including gut-associated mesenteric lymph 
nodes, but lacked Peyer’s patches. RORγtM interfered with ubiquitination of RORγt at 
lysine 69 (K69). Similar to RORγtM, mutation of K69 to arginine (K69R) to prevent 
ubiquitination selectively impaired RORγt-mediated TH17 differentiation but not thymocyte 
development. Our study thus distinguishes between RORγt function in TH17 differentiation 
and thymocyte development, and reveals distinct mechanisms for these two RORγt-
regulated processes.
Results
RORγt supports in vitro T cell development and TH17 differentiation
To evaluate the function of RORγt function in TH17 differentiation and thymocyte 
development, we investigated the structural requirements of the RORγt protein for these two 
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functions. In an in vitro differentiation system, sorted CD4−CD8− (DN) thymocytes from 
wild-type and RORγt−/− mice were cultured on OP9-DL4 stromal cells to induce 
differentiation 20. Wild-type, but not RORγt−/− DN thymocytes differentiated into 
CD4+CD8+ DP and CD4+ (CD4SP) thymocytes (Fig. 1a). Both wild-type and RORγt−/− DN 
thymocytes were negative for RORγt expression, but DP thymocytes differentiated from 
wild-type DN thymocytes expressed RORγt (Fig. 1b). Consistent with previous observation, 
RORγt was up-regulated in DP thymocytes and was required for their survival 5, 7, 18. A 
population of TCRloCD24hiCD8+ thymocytes developed from both wild-type and RORγt−/− 
DN thymocytes (Supplementary Fig. 1a) prior to the DP stage 21. Thus, we used the 
percentage of CD4+ cells, including both CD4+CD8+ DPs and mature CD4+ SPs, to evaluate 
the efficiency of thymocyte development (Fig. 1a, right panel). To assess the role of RORγt 
in thymocyte development, we transduced RORγt−/− DN thymocytes with a retrovirus 
expressing RORγt-GFP or empty virus alone (EV-GFP) as control. Thymocyte development 
was rescued only in RORγt-GFP+ cells, but not in EV-GFP+ cells (Fig. 1c) or in GFP- cells 
that were not transduced by virus (Supplementary Fig. 1b). Furthermore, thymocyte 
development was not rescued by expression of RORγt mutants that cannot bind target DNA 
(RORγt-DBD) or the co-activator SRC (RORγt-AF2) (Fig. 1c), although both mutants were 
expressed at the equivalent levels as wild-type RORγt (Supplementary Fig. 1c), consistent 
with the notion that DNA-binding activity and AF2-mediated recruitment of co-activator 
SRC are required for RORγt to support thymocyte development 18.
To establish an in vitro TH17 differentiation assay, splenic CD4+ T cells isolated from wild-
type or RORγt−/− mice were cultured in TH17 priming conditions. RORγt−/− CD4+ T cells, 
but not wild-type CD4+ T cells, were defective in TH17 differentiation (Fig. 1d), and lacked 
RORγt expression (Supplementary Fig. 1d). TH17 differentiation of RORγt−/− T cells was 
rescued in retrovirally transduced RORγt-GFP+ cells, but not EV-GFP+ (Fig. 1e) or in GFP− 
non-transduced cells (Supplementary Fig. 1e). Similar to RORγt-mediated T cell 
development, retroviral expression of RORγt-DBD and RORγt-AF2 at the same level as 
RORγt-GFP (Supplementary Fig. 1f) failed to rescue Th17 differentiation (Fig. 1e). 
Therefore, both T cell development and TH17 differentiation depend on RORγt DNA-
binding activity and AF2-mediated recruitment of co-activator SRC. Consistent with RORγt 
up-regulation of anti-apoptotic Bcl-xL to enhance thymocyte survival 5, 7, retroviral 
expression of anti-apoptotic Bcl-xL (Bcl-xL-GFP) partially rescued differentiation of DP 
thymocytes from RORγt−/− thymocytes (Fig. 1f). However, Bcl-xL-GFP could not rescue 
TH17 differentiation in RORγt/− T cells (Fig. 1g), indicating distinct mechanisms involved 
in RORγt-regulated TH17 differentiation and thymocyte development.
Two amino acids are critical for TH17 differentiation but not T cell development
As mutations affecting the RORγt DNA-binding activity and the AF2 motif of ligand-
binding domain interfered with both thymocyte development and TH17 differentiation, we 
extended the search for structural RORγt elements differentially required for these functions 
by introducing mutations in the RORγt hinge domain. By mutating consecutive stretches of 
five amino acids to alanines (alanine scanning), we created 33 mutants covering the hinge 
region (amino acids 76–240, Fig. 2a). RORγt−/− DN thymocytes or peripheral RORγt−/− 
CD4+ T cells transduced with retroviruses expressing RORγt-GFP or alanine-mutant 
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RORγt were assessed for rescued thymocyte development and TH17 differentiation in vitro, 
as described above. 20 out of 33 mutants such as 176–180A and 191–195A (supplementary 
Fig. 1g) rescued both thymocyte development and TH17 differentiation. Seven mutants (e.g. 
76–80A in Fig. 2b and 181–185A in supplementary Fig. 1g) markedly impaired both 
thymocyte development and TH17 differentiation. These mutants were scattered across the 
entire hinge domain (Fig. 2c, top panel), indicating that functionally important motifs of 
RORγt for both functions are not clustered together.
Six mutants, including 91–95A (Fig. 2b) and 151–155A (Supplementary Fig. 1g) 
preferentially impaired TH17 differentiation, with limited effect on thymocyte development, 
indicating a selective requirement of these two regions (amino acids 91–105 and 151–165) 
for TH17 differentiation (Fig. 2c, top panel). 151–165 mutants maintained more than 50% 
activity during TH17 differentiation, while mutant 91–95A maintained the majority of 
activity in thymocyte development, but could not support TH17 differentiation (Fig. 2c, top 
panel). When expressed as the ratio of the percentage of rescued thymocyte development 
versus percentage of rescued TH17 differentiation, mutant 91–95A showed the biggest 
difference between the ability to support thymocyte development and inability to support 
TH17 differentiation (Fig. 2c, bottom panel).
We further defined which amino acids were critical for distinguishing between the two 
RORγt-regulated functions in mutant 91–95A. The amino acid sequence from 91–95 is 
DSLHA and our alanine scan did not change the last A. To investigate the requirement for 
the first four amino acids, we created two three-alanine mutants covering these four amino 
acids: 91–93A and 92–94A. Similar to mutant 91–95A, 91–93A and 92–94A supported 
thymocyte development (Fig. 2d, top panel), but neither supported TH17 differentiation (Fig. 
2d, bottom panel) when retrovirally expressed in RORγt−/− T cells. Additionally, a S92A-
L93A mutant rescued thymocyte development (Fig. 2e, top panel) but not TH17 
differentiation (Fig. 2e, bottom panel) in RORγt−/− T cells. The single mutant S92A 
preserved both functions, whereas mutant L93A significantly impaired both thymocyte 
development and TH17 differentiation (Fig. 2e). Immunoblotting confirmed that all mutants 
were expressed at equivalent levels with wild-type RORγt (Supplementary Fig. 1h). S92A-
L93A was the minimum mutation sufficient to distinguishly regulate RORγt-dependent 
thymocyte development and TH17 differentiation (Fig. 2f). We have thus identified a RORγt 
mutation (hereafter called RORγtM) that specifically disrupts RORγt-mediated TH17 
differentiation, but not thymocyte development.
RORγtM cannot induce genes critical for Th17 differentiation
Th17 differentiation depends on RORγt-regulated gene expression 22. To assess the global 
effects of RORγtM on TH17 differentiation, we performed RNA sequencing (RNA-seq) and 
chromatin immunoprecipitation-DNA-seq (ChIP-seq) analyses of RORγt−/− T cells 
transduced with retrovirus expressing GFP only (EV-GFP), RORγt-GFP or RORγtM-GFP 
(Fig. 3). The flag-tag fused to RORγt to immunoprecipitate RORγt-binding DNA fragments 
for ChIP did not affect RORγt expression or function in Th17 differentiation 
(Supplementary Fig. 2a,b). We found similar expression patterns between RORγt−/− T cells 
reconstituted with EV-GFP and RORγtM-GFP, which was different for RORγt−/− T cells 
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reconstituted with RORγt-GFP (Fig. 3a), an observation confirmed by hierarchical 
clustering analysis (Fig. 3a). Many TH17 signature genes, including Il17a, Il17f, Il23r, Il1r, 
Ccr6, IL-17re and Il22 were down-regulated in EV-GFP+RORγt−/− T cells compared to 
RORγt-GFP+RORγt−/− T cells (Fig. 3b, left panel), confirming the defective Th17 
differentiation. These TH17 signature genes were also down-regulated in RORγtM-
GFP+RORγt−/− T cells compared to RORγt-GFP+RORγt-−/− T cells (Fig. 3b, right panel). 
ChIP-seq identified 21,917 RORγt-DNA binding peaks within gene loci such as Il17 and 
Il23r (Fig. 3c) as well as Il1r, Il17re, Rorc and Ccr6 (Supplementary Fig. 2c) known to be 
critical for TH17 differentiation. Of 3,931 RORγtM-DNA binding peaks identified in 
RORγtM-GFP+ cells, almost all (3886 out of 3931) overlapped with RORγt-DNA binding 
peaks. However, RORγtM lost or showed significantly reduced DNA-binding peaks within 
important TH17 gene loci (Fig. 3c and supplementary Fig. 2c), which correlated with their 
diminished expression (Fig. 3b). Greatly deduced binding to Il17 and Il23r loci by RORγtM 
compared to RORγt was confirmed by individual ChIP assays (Fig. 3d). Therefore, 
RORγtM selectively loses DNA-binding sites and ability to activate genes required for TH17 
differentiation.
RORγtM supports thymocyte development in vivo
To test the in vivo function of RORγtM, we knocked-in exon 4, which contains the coding 
sequence for the two critical amino acids (S92-L93), in the RORγt locus (Supplementary 
Fig. 3a). A neomycin gene used for selection was also deleted by flp recombinase 
(Supplementary Fig. 3b) to avoid interfering with gene expression. RORγtM expression was 
indicated by the detection of S92A-L93A mutations by sequence analysis of RORγt mRNA 
(Supplementary Fig. 3c). Mice expressing RORγtM from the endogenous RORγt locus are 
called RORγtM/M hereafter. We first examined T cell development in RORγtM/M mice. 
Intracellular staining of RORγt showed equivalent expression of RORγtM and RORγt in 
CD4+CD8+ DPs of corresponding mice (Supplementary Fig. 4a), suggesting appropriate 
RORγtM expression during T cell development. RORγt−/− mice had dramatically reduced 
thymic cellularity (Fig. 4a) due to accelerated spontaneous apoptosis (Fig. 4b), while the 
thymic cellularity and survival of RORγtM/M thymocytes were almost equivalent to that of 
wild-type mice (Fig. 4a, b). Based on the surface CD44 and CD25 markers, DN thymocyte 
development in RORγt−/− or RORγtM/M mice was similar to wild-type (Supplementary Fig. 
4b) 5. The percentage (Fig. 4c) and absolute number (Supplementary Fig. 4c) of CD4+ and 
CD4+CD8+ DP were reduced in RORγt−/− thymus compared to wild-type mice, while 
RORγtM/M mice had similar percentage and number of CD4+ and CD4+CD8+ DP cells to 
those detected in wild-type mice. Moreover, while CD8+ thymocytes in RORγt−/− mice 
were mostly immature TCRloCD24hi, CD8+ cells in RORγtM/M thymi were mostly 
TCRhiCD24lo mature cells, similar to wild-type mice (Fig. 4d). Compared to the enlarged 
cell size (FSC) (Fig. 4e) and markedly increased number of cells entering DNA synthesis (S) 
phase of the cell cycle, indicated by cells with >2N DNA (Fig. 4f) in RORγt−/− mice, 
RORγtM/M thymocytes had the same cell size and percentage of cells in S phase as the wild-
type mice (Fig. 4e, f). In addition, RNA-seq indicated that the most prominent apoptotic 
molecule up-regulated in wild-type thymocytes compared to the RORγt−/− thymocytes was 
Bcl-xL (encoded by Bcl2I1) (Fig. 4g). Many cell cycle regulators, including cyclins and cell 
division cycle proteins, displayed changes greater than 2-fold in RORγt−/− vs wild-type 
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thymocytes(Fig. 4g, top panel), consistent with the survival and cell cycle changes observed 
in RORγt−/− thymocytes. Changes in the expression of Bcl-xL and cell cycle molecules were 
significantly less pronounced between RORγtM/M and wild-type thymocytes (Fig. 4g, 
bottom panel) than between RORγt−/− and wild-type thymocytes (Fig. 4g, top panel), 
suggesting that RORγtM/M thymocytes were phenotypically equivalent to wild-type, but not 
RORγt−/− thymocytes. As such, RORγtM functions largely similarly to endogenous RORγt 
in supporting thymocyte development in vivo.
RORγtM/M mice have defective TH17 differentiation
The distribution of naïve and memory T cells in RORγtM/M mice was similar to that 
observed in wild-type mice (Supplementary Fig. 5a,b). To determine the function of 
RORγtM in TH17 cells, we differentiated naïve spenic T cells from wild-type, RORγtM/M 
and RORγt−/− mice under Th1, TH17, Th2 or Treg conditions. In contrast to wild-type T 
cells, and similar to RORγt−/− T cells, RORγtM/M T cells failed to differentiate into IL-17 
producing cells (Fig. 5a, bottom panel), while there were no obvious differences in their 
ability to differentiate into TH1 (Fig. 5a, top panel), TH2 (Supplementary Fig. 5c) or Treg 
cells (Supplementary Fig. 5d) compared to wild-type cells, suggesting a selective defect in 
TH17 differentiation. In in vitro-differentiated TH17 cells, RORγtM protein expression was 
equivalent to RORγt in wild-type cells (Fig. 5b), suggesting that defective TH17 
differentiation was not due to lack of RORγtM expression. Development of EAE was 
attenuated in both RORγt−/− and RORγtM/M mice, compared to wild-type mice (Fig. 5c), 
with greatly reduced numbers of infiltrated CD45+ lymphocytes, including Ly6G+ 
neutrophils, CD3+ T cells, CD19+ B cells, and CD11b+ monocytes recovered from the 
central nervous system (CNS) of RORγt−/− and RORγtM/M mice compared to wild-type 
mice (Fig. 5d, Supplementary Fig. 6a), indicating reduced inflammation. Analysis of 
infiltrated lymphocytes indicated reduced expression of Il17a, Ifng and Csf2 mRNA in 
RORγtM/M and RORγt−/− mice compared to wild-type mice (Fig. 5e). Adoptive transfer of 
naïve CD4+ T cells into Rag1−/− mice followed by induction of EAE also induced greatly 
attenuated EAE in Rag1−/− mice reconstituted with RORγt−/− or RORγtM/M CD4+ T cells, 
in contrast to Rag1−/− mice reconstituted with wild-type CD4+ T cells (Fig. 6a), with 
reduced numbers of infiltrated lymphocytes, including Ly6G+ neutrophils, CD4+ T cells and 
CD11b+ monocytes (Fig.6b and supplementary Fig. 6b) and decreased Il17a, Ifng and Csf2 
mRNA expression in infiltrating cells (Fig. 6c,d). Il17a mRNA was the most reduced, 
consistent with the greatest reduction in the percentage (Fig. 6e) and absolute number (Fig. 
6f) of IL-17+IFNγ+ and IL-17+GM-CSF+ T cells, which are believed to be pathogenic for 
EAE 3, 4, 23. In contrast, the overall percentage of IFNγ+ and GM-CSF+ cells in RORγt−/− 
or RORγtM/M reconstituted Rag1−/− mice were not obviously changed compared to wild-
type reconstituted Rag1−/− mice (Fig. 6e,f), demonstrating selective defects in the 
differentiation of TH17 cells. A similar specific reduction of IL-17+ cells, but not IFN-γ+ 
cells was also observed in CD4+ T cells from draining lymph nodes, and to a lesser extent in 
CD4+ T cells from spleens (Supplementary Fig. 6c). We did not observe differences in the 
expression of Foxp3 in T cells from EAE-induced wild-type and RORγtM/M mice 
(Supplementary Fig. 6d).
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Next we assessed the ratio of representative pathogenic and nonpathogenic gene expression 
in wild-type and RORγtM/M CD4+ T cells differentiated with either TGF-β + IL-6 or 
pathogenic TGF-β + IL-6 + IL-23 TH17 priming conditions. The expression of 
nonpathogenic genes did not generally change more than 2 fold between wild-type and 
RORγtM/M T cells in either priming conditions (Fig. 6g). However, many pathogenic genes 
showed higher expression in wild-type compared to RORγtM/M T cells under non-
pathogenic priming conditions (Fig. 6g). Some pathogenic genes had lower expression in 
wild-type compared to RORγtM/M T cells, but usually less than 2 fold change (Fig. 6g). All 
the pathogenic genes detected were expressed higher in wild-type than in RORγtM T cells in 
the presence of IL-23 (Fig. 6g). When analyzing pathogenic and nonpathogenic gene 
expression in T cells obtained from EAE-induced mice, many pathogenic genes showed 
higher expression in wild-type T cells, whereas some showed lower expression in wild-type, 
but usually less than 2 fold change compared to RORγtM T cells (Fig. 6h). Therefore, 
RORγtM/M T cells showed lower pathogenic potential, a loss of function in supporting TH17 
differentiation and induction of EAE in vivo.
RORγtM/M mice develop lymph nodes, but not Peyer’s patches
Because RORγt−/− mice typically lack all lymph nodes 5, we examined lymph nodes 
development in RORγtM/M mice. In contrast to RORγt−/− mice, RORγtM/M mice had 
almost all lymph nodes examined, including aorta lymph nodes and gut-associated 
mesenteric lymph nodes (Table 1 and Fig. 7a). While inguinal lymph nodes were developed 
but smaller than those found in wild-type mice, reflected by the reduced cellularity (Fig. 7a). 
Consistently, the number of ILC3, which are enriched for lymphoid tissue inducer (LTi) was 
comparable to wild-type in mesenteric lymph nodes of RORγtM/M mice (Supplementary 
Fig. 6e, f). However, RORγtM/M mice failed to develop Peyer’s patches similar to RORγt−/− 
mice (Table 1 and Fig. 7a), consistent with the evidence indicating that development of 
Peyer’s patches and other peripheral lymph nodes depend on different pathways 24, 25. 
RORγtM is thus able to support the development of most lymph nodes, except Peyer’s 
patches.
RORγtM interferes with the ubiquitination of RORγt at lysine 69
To understand how the two-alanine mutation in RORγtM affects RORγt function, we first 
monitored RORγtM activity using a RORγt-luciferase reporter. RORγt recruits the 
transcription co-activator SRC1 via an AF2 motif within the ligand-binding domain 18, 26. 
RORγtM interacted with SRC1 and stimulated RORγt reporter activity similarly to wild-
type RORγt (Supplementary Fig. 7a,b). RORγt is ubiquitinated in TH17 cells 26. 
Comparison of the RORγt ubiquitination patterns in cells isolated from wild-type, RORγt−/− 
and RORγtM/M mice indicated that the ubiquitination of RORγtM was reduced in 
differentiated TH17 cells (Fig.8a, left panel) and thymocytes (Fig.8a, right panel). We then 
immunoprecipitated RORγt and RORγtM for mass spectrometric analysis of ubiquitinated 
lysines (K). Digesting ubiquitinated K leaves a GG isopeptide linked to K, which can be 
easily detected using mass spectrometry as an increased mass of 114.102 Da 27. We detected 
ubiquitination signals at lysine 69 (K69) in wild-type RORγt, but not RORγtM 
immunoprecipitated from differentiated TH17 cells (data not shown). We then monitored 
RORγt ubiquitination in HEK 293T cells transfected with wild-type RORγt or RORγtM and 
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HA-tagged ubiquitin, followed by immunoprecipitation for RORγt. Ubiquitinated RORγtM 
was reduced compared to wild-type RORγt (Fig. 8b). To specifically evaluate K69 
ubiquitination, we generated a mutant RORγt in which all 23 lysines, except K69, were 
mutated to arginines (RORγt-K69), so that only K69 can be ubiquitinated. RORγt-K69 was 
polyubiquitinated at K69 in HEK 293T cells (Fig. 8b), while introduction of the L92A-S93A 
mutation to RORγt-K69 (RORγtM-K69) markedly impaired K69 ubiquitination (Fig. 8b), 
confirming that two amino acid mutations in RORγtM interfere with K69 ubiquitination. 
Mutant 91–95A, but not three alanine scanning mutants 151–155A, 156–160A and 161–
165A greatly impaired RORγt ubiquitination at K69 (Supplementary Fig.7c). We next 
determined whether the polyubiquitin chains on RORγt-K69 were K63- or K48-linked 28. 
Mutating all seven Ks within HA-ubiquitin to arginines [K(7)R] or mutating only K63 to 
arginine (K63R) prevented RORγt-K69 ubiquitination, whereas mutating all Ks within HA-
ubiquitin except K63 to arginines (K63) did not affect RORγt-K69 ubiquitination (Fig. 8c). 
This suggests the formation of K63-linked polyubiquitin chains at RORγt K69 residue. In 
contrast, mutating K48 of HA-ubiquitin to arginine (K48R) did not affect RORγt-K69 
ubiquitination, whereas mutating all Ks of HA-ubiquitin except K48 to arginines (K48) 
prevented RORγt-K69 ubiquitination (Fig. 8c), indicating that polyubiquitin chains at 
RORγt K69 were not K48-linked. An important function of ubiquitination is to regulate 
protein degradation 28, ubiquitination was reported to regulate RORγt stability 29, 30, 31, 32. 
However, RORγtM protein expression showed no difference compared to wild-type RORγt 
at various times after treatment of differentiated TH17 cells with the protein synthesis 
inhibitor cycloheximide (CHX) (Supplementary Fig. 7d,e), indicating that the degradation 
rate of RORγtM was same as wild-type RORγt and correlating with the observation that 
changes in RORγtM ubiquitination were not due to K48-linked polyubiquitin chains that 
target proteins for degradation 28.
To determine the function of K69 ubiquitination in RORγt-regulated function, we mutated 
RORγt K69 to arginine (mutant K69R) to prevent ubiquitination. As a control, we mutated 
RORγt K81 to arginine (mutant K81R), as K81 was not ubiquitinated in mass spectrometric 
analysis. K69R interacted with SRC1 and stimulated RORγt reporter activity similar to 
RORγtM and RORγt in HEK 293T cells (Supplementary Fig. 7b,f). In thymocyte 
development and TH17 differentiation assays, retroviral expression of K69R rescued 90% of 
thymocyte development in RORγt−/− thymocytes, similar to wild-type RORγt and K81R, 
and slightly greater than thymocyte development supported by RORγtM (Fig. 8d,e), 
suggesting that K69 ubiquitination is not essential for RORγt-mediated thymocyte 
development. In contrast, K69R rescued only about 45% of TH17 differentiation in 
RORγt−/− T cells, which was markedly reduced compared to wild-type RORγt and K81R 
(Fig. 8d,e), and correlated with reduced expression of TH17 signature genes, including Il17a, 
IL17f, and Ccl20 (Fig. 8f), as well as binding to the IL-17 promoter (Fig. 8g) in K69R-
transduced RORγt−/− T cells. Therefore, K69 ubiquitination, although dispensable for 
thymocyte development, is required to promote TH17 differentiation. However, because 
K69R was more potent than RORγtM in supporting TH17 differentiation, lack of K69 
ubiquitination is only partially responsible for failed Th17 differentiation observed in the 
RORγtM/M T cells.
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Discussion
In this study, we identified a two amino acid mutation in the hinge region of RORγt that 
allows normal thymocyte development, but not TH17 differentiation. While RORγt−/− mice 
exhibit multiple defects, including thymocyte and ILC3 development, lymph node genesis 
and TH17 differentiation, RORγtM/M mice exhibited a specific defect in Th17 
differentiation, while maintaining thymocyte development. RORγtM/M mice also developed 
ILC3 cells, but these ILC3 were defective in the production of IL-17 cytokine (data not 
shown). Therefore, RORγtM preserves the function to instruct T and ILC3 development, but 
selectively disrupts the IL-17 production function of mature cells. We further demonstrated 
that the two amino acid mutation impaired ubiquitination of RORγt at K69 that is 
selectively required for TH17 differentiation but not thymocyte development.
RORγt−/− mice have a high incidence of thymic lymphoma, likely due to dysregulated 
thymocyte development, including cell cycle and apoptosis changes 6. Because thymocyte 
development in RORγtM mice is largely normal, lymphoma development seems unlikely. 
Indeed, we did not detected lymphoma among more than 160 RORγtM mice analyzed, 
including 25 mice 24 week old, 8 mice 37–39 week old and 7 mice older than 39 weeks 
(results not shown), while more than 50% of RORγt−/− mice die of lymphoma prior to 39 
week of age 6. These result support the idea that lymphoma in RORγt−/− mice results from 
abnormal thymocyte development.
The RORγt S92A-L93A mutations were the minimum alterations in the hinge region that 
selectively disrupted RORγt function in TH17 differentiation without affecting thymocyte 
development. Although S92 is a potential phosphorylation site, mutant S92A, which cannot 
be phosphorylated, did not affect RORγt function. In contrast, mutant L93A affected both 
RORγt-mediated thymocyte development and TH17 differentiation. Whereas, two amino 
acid mutation, S92A-L93A (RORγtM), can maximally separate RORγt function in 
thymocytes and TH17 differentiation. RORγtM did not affect RORγt activity, recruitment of 
the co-activator SRC1 and stimulation of a RORγt reporter, suggesting that two amino acid 
mutation does not affect overall RORγt function. However, RORγtM impairs the 
ubiquitination of K69 that is required for TH17 differentiation, but not thymocyte 
development. Therefore, post-translational ubiquitination plays an important role in 
distinguishing RORγt function in TH17 differentiation versus thymocyte development. 
Although ubiquitination is known to regulate protein degradation 28, K69R and RORγtM do 
not affect RORγt protein levels, and thus does not support the function of K69 
ubiquitination in the regulation of RORγt stability. This is further confirmed by K63- but not 
K48-linked ubiqutination at K69 of RORγt. The fact that K69 locates in the DNA-binding 
domain and K69R impairs RORγt-binding to the IL-17 locus supports that RORγtM affects 
DNA-binding activity selectively in TH17 cells via interfering with K69 ubiquitination. This 
possibility is strengthened by our global analysis indicated that RORγtM failed to bind and 
stimulate genes critical for TH17 differentiation, whereas it did not significantly affect the 
expression of cell survival and cell cycle genes critical for thymocyte development. It still 
remains to be determined how K69 ubiquitination is selectively required for TH17 
differentiation but not thymocyte development. One of the possibilities is that K69 
ubiquitination induces the recruitment of a co-factor to RORγt specifically in Th17 cells, 
He et al. Page 9
Nat Immunol. Author manuscript; available in PMC 2018 February 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
which can be determined by comparing RORγt-associated proteins between Th17 cells and 
thymocytes. In addition, the enzymes responsible for modifying K69 of RORγt remain 
unknown. Identification of these enzymes will facilitate the development of drugs that 
specifically target RORγt-mediated pathological autoimmune TH17 responses, without 
interfering with thymocyte development or lymph node genesis.
RORγt mutations reported in humans result in susceptibility to fungal and mycobacteria 
infection 33. However, these RORγt mutations locate in either the DNA-binding domain or 
the ligand-binding domain. Humans bearing RORγt mutations also have defects in lymph 
node genesis and thymocyte apoptosis 33, consistent with the phenotypes observed in 
RORγt−/− mice, and suggesting function conservation between human and mouse RORγt. It 
will be important to investigate if modifications of the S92-L93 motif identified in mice also 
distinguishes the thymocyte development and Th17 differentiation function of RORγt in 
humans.
Materials & Methods
Mice
The RORγt−/− (Rorc2−/−) mouse strain was described previously 5. Both the targeting vector 
and the knock-in RORγtM/M mice were designed and generated by Biocytogen LLC. Rosa-
Flp (008600) and Rag1−/− (002216) mice were purchased from the Jackson Laboratory. For 
all experiments, mice were 6–12 weeks of age; age-matched littermates were used in 
experimental groups, and all groups contained five mice unless stated otherwise. Mice were 
bred and housed under specific pathogen-free (SPF) conditions in the Animal Resource 
Center at the Beckman Research Institute of City of Hope under protocols approved by the 
Institutional Animal Care and Use Committee.
Plasmids and Retrovirus
The retroviral vector MIGR (murine stem cell virus [MSCV]-IRES-GFP) was a gift from Dr. 
Warren S. Pear (University of Pennsylvania, Philadelphia, PA) and used to clone RORγt or 
BCL-xL cDNA as described previously. Mutant RORγt vectors were prepared using a site-
directed mutagenesis kit from Agilent Technologies. pRK5-HA-ubiquitin constructs (a gift 
from Ted Dawson, Addgene #17603 -17608) for expressing HA-tagged wild-type and 
mutant ubiquitin were obtained from Addgene. Retroviruses were packaged in a Platinum-
Eco cell line from Cell Biolabs as described previously 26. Briefly, retroviral expression 
plasmids were transfected into Platinum-Eco packaging cells using Lipofectamine 2000 
(thermofisher scientific). Viral supernatants were collected 72 h later, passed through 0.4-μm 
filters, and stored at −80°C until use.
Flow cytometry and cell sorting
Tissues were homogenized by crushing with the head of a 1-ml syringe in a petri dish, 
followed by straining through a 40-μm nylon filter. Red Blood Cell Lysing buffer (Sigma-
Aldrich) was used for red cell lysis and remaining cells were counted. Antibodies used for 
flow cytometry staining are listed in Supplementary Table 1. For intracellular cytokine 
staining, cells obtained from in vitro cultures were incubated for 4–5 h with 50 ng/ml PMA, 
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750 ng/ml ionomycin (both from Sigma-Aldrich), and 10 μg/ml brefeldin A (BD 
Biosciences) in a tissue culture incubator at 37°C. Cells were resuspended in Fixation/
Permeabilization solution and intracellular cytokine staining was performed (BD Cytofix/
Cytoperm Kit; BD Biosciences). For sorting double-negative thymocytes, thymocytes from 
C57BL/6 or RORγt−/− mice were stained with 7-AAD and antibodies against Thy1.2, CD4 
and CD8 (listed in Life Sciences Reporting System item 9). Specific Thy1.2+/CD4−/CD8− 
populations were sorted using a FACSAria (BD Biosciences).
T cell development assay
Electronically sorted double-negative thymocytes (Thy1.2+/CD4−/CD8−) were cultured at 
5×105/ml overnight on an 80% confluent OP9-DL4 monolayer (generous gift from Dr. Ellen 
Rothenberg, Caltech) in flat-bottom 24-well culture plates with αMEM (MEM α medium; 
Invitrogen Life Technologies) supplemented with 20% FBS, 100 U/ml penicillin-
streptomycin, 2 mM L-glutamine (Invitrogen Life Technologies), and 5 ng/ml recombinant 
murine IL-7 (PeproTech). The following day, co-cultures were transduced by spin infection 
(1200 g, 30°C for 2 h) using retroviral supernatants in the presence of 8 mg/ml polybrene 
(Sigma-Aldrich). After spin infection, viral supernatant was replaced with culture media 
containing 5 ng/ml recombinant murine IL-7. 72 h post-transduction, co-cultures were 
harvested for flow cytometry analysis.
CD4+ T cell isolation and in vitro TH17 differentiation assay
Naive CD4+ T cells were purified from C57BL/6, RORγt−/−, or RORγtM/M mice by 
negative selection using CD4+ T Cell Isolation Kit II (Miltenyi Biotec). Suspensions of 
4×105 cells/ml Iscove’s modified DMEM (Cellgro) containing 2 mM L-glutamine, 50 mM 
2-ME, 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% FBS were cultured in 24-well 
plates pre-coated with 0.2 mg/ml goat anti-hamster antibody (MP biomedicals) for three 
days. The medium was supplemented with 0.25 μg/ml hamster anti-CD3 (145-2C11; 
eBioscience), 1 μg/ml hamster anti-CD28 (37.51; eBioscience), and polarizing cytokines: 2 
ng/ml TGF-β (Peprotech), 20 ng/ml IL-6 (Peprotech), 5 μg/ml anti-IL-4 (11B11), and 5 
μg/ml anti-IFNγ (XMG 1.2) for TH17 differentiation; 20 ng/ml IL-23 (Miltenyi Biotec) was 
also added when inducing pathogenic TH17 cells. 20 ng/ml IL-12 (Peprotech) and 5 μg/ml 
anti-IL-4 for TH1 differentiation; 10 ng/ml IL-4 and 10 μg/ml anti-IFNγ for TH2 
differentiation; or 5 ng/ml TGF-β for Treg differentiation. For retroviral transduction, T cells 
were first activated with 0.25 μg/ml hamster anti-CD3 (145-2C11; eBioscience), 1 μg/ml 
hamster anti-CD28 (37.51; eBioscience) in 24-well plates pre-coated with 0.2mg/ml goat 
anti-hamster antibody for 24 h, then spin-infected with viral supernatants (1200 g, 30°C for 
2 h) in the presence of 8 mg/ml polybrene (Sigma-Aldrich). After spin infection, viral 
supernatant was replaced by culture media with polarizing cytokines for in vitro 
differentiation.
RNA sequencing (RNA-seq) and analysis
To measure gene expression in the thymus of C57BL/6, RORγt−/− or RORγtM/M mice, two 
separate samples were collected on different days, and thymocytes from four (two male and 
two female) were pooled each day. For demonstrating the gene expression profile regulated 
by wild-type RORγt or RORγtM/M in in vitro-differentiated Th17 cells, CD4+ T cells were 
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enriched from RORγt−/− mice, transduced with retrovirus containing empty vector, wild-
type RORγt or RORγtM/M, then polarized under Th17 conditions for three days. Cells were 
processed for RNA isolation (Qiagen). Quality verification, library preparation, and 
sequencing were performed at City of Hope Integrative Genomics Core facility. Samples 
were sequenced on an IlluminaHiSeq 2000 using 75-bp paired end reads. Reads were 
aligned to the mm9 mouse genome using TopHat version 2.1.0 and Bowtie version 1.1.1. 
Differential expression was computed with Cufflinks version 2.2.1. Differentially expressed 
genes were filtered by significance at FDR-adjusted P < 0.05, and the ratio of fragments per 
kilobase of transcript per million mapped reads (FPKM) were at least two-fold changes 
between two of the populations. Clustering and heatmapping were performed using 
hierarchical clustering in R with pheatmap package version 1.0.8. For heat maps, expression 
values were scaled per gene.
Chromatin immunoprecipitation and DNA sequencing (ChIP-seq)
2×107 cells were incubated with 1% formaldehyde, to cross-link proteins with chromatin, 
for 5 min at room temperature. 125 mM glycine was added to stop the cross-linking 
reaction. To shear genomic DNA into 200–500 bp fragments, cell lysates were sonicated 
using a water-bath sonicator (Covaris S200). Cell lysates were centrifuged (12000 g, 10 min) 
and incubated with FLAG antibody (M2, Sigma-aldrich, listed in Life Sciences Reporting 
System item 9) or IgG controls, and magnetic protein A/G beads (Millipore). After extensive 
washing, DNA was eluted followed by reversion of the protein–DNA cross-linking. DNA 
was recovered for DNA-seq or qRT-PCR to quantify specific DNA fragments that were 
precipitated. Primers used in qRT-PCR were listed in Supplementary Table 1. Samples were 
sequenced on an IlluminaHiSeq 2000 using 75-bp paired end reads. Reads were aligned to 
the mm9 mouse genome using Bowtie version 1.1.1. Differential peaks were computed with 
MACS version 1.4.2 and bedtools version 2.17.0. Neighboring genes in the mm9 mouse 
genome were searched using webtools Cistrome Analysis Pipeline (at website: 
Cistrome.org/ap).
Quantitative real-time PCR (qRT-PCR)
qRT-PCR was performed using SsoFast EvaGreen Supermix (Bio-Rad) in a CFX96 Real-
Time PCR Detection System (Bio-Rad), using primers as noted (Supplementary Table 1). 
The amplification efficiency of all primers has been tested, and the optimized conditions 
were used in all qRT-PCR reactions. Expression was calculated with the ΔΔxp method 
normalized to β-actin, and all measurements were performed in triplicate.
Apoptosis assays
Thymocytes were freshly isolated from wild-type, RORγt−/−, or RORγtM/M mice and 
cultured in RPMI 1640 medium supplemented with 10% FBS, 100 U/ml penicillin-
streptomycin, 2 mM L-glutamine at 1×106 cells/ml. Thymocytes were incubated at 37°C 
with 5% CO2. Dead cells were detected by Annexin V-PE and 7-AAD staining (BD 
Bioscience), as described previously 34.
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Induction and assessment of Experimental Autoimmune Encephalomyelitis (EAE)
Active EAE was induced and assessed as previously described 35. Briefly, mice were 
immunized subcutaneously in the abdominal flank with 200 mg MOG35-55 and 400 mg 
Mycobacterium tuberculosis H37RA (Difco) in a 400 μl emulsion of equal volumes of water 
and complete Freund’s adjuvant (Difco). Each mouse also received 0.4 mg purified 
Bordetella pertussis toxin in 200 μl PBS intraperitoneally on days 0 and 1. For reconstitution 
of T cells in Rag1−/− mice, 5×106 flow cytometry-sorted CD4+ T cells from C57BL/6, 
RORγt−/−, or RORγtM/M mice were intraperitoneally transferred into Rag1−/− mice, 
followed by active induction of EAE.
Western blot and immunoprecipitation
Cells were lysed in lysis buffer (0.5% Triton X-100, 20 mM HEPES, pH 7.4, 150 mM NaCl, 
12.5 mM β-glycerophosphate, 1.5 mM MgCl2, 10 mM NaF, 2 mM dithiothreitol, 1 mM 
sodium orthovanadate, 2 mM EGTA, 20 mM aprotinin, 1 mM phenylmethylsulfonyl 
fluoride). Protein from cell extracts (15 mg) was resolved using SDS-PAGE (10% gel), 
transferred to PVDF Membrane (Millipore), and Western blot was performed using relevant 
antibodies. Immunoprecipitation experiments were performed as described previously. In 
brief, cell extracts were incubated overnight with relevant antibodies and protein A/G beads 
at 4°C. After incubation, beads were washed four times with lysis buffer, resolved using 
SDS-PAGE, and analyzed using Western blot. Western blot primary antibodies were listed in 
Life Sciences Reporting System item 9.
Enrichment of ubiquitinated proteins by Agarose-TUBE1
A total of 1.5×108 thymocytes from C57BL/6, RORγt−/−, or RORγtM/M mice, or 1.5×108 
Th17 cells differentiated in vitro as described above, were lysed in 500 μl cell lysis buffer 
(50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1% NP-40, 10% glycerol, 1 mM 
PMSF). Cell lysates were incubated with 20 μl equilibrated Agarose-coupled Tandem 
Ubiquitin Binding Entity 1 (Agarose-TUBE1) (LifeSensors) at 4°C for 4 h. Agarose-TUBE1 
was washed with 1 ml TBS-T (20 mM Tris-HCl [pH 8], 150 mM NaCl, 0.1% Tween-20) 
and suspended in SDS reducing sample buffer. Eluted samples were analyzed by Western 
blotting.
Statistical analysis
Prism software (Graphpad) was used for all statistical analyses. Unpaired Student’s t tests 
and one-way analysis of variance (ANOVA) were used to compare experimental groups. A P 
value of less than 0.05 was considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. RORγt supports in vitro T cell development and TH17 differentiation
(a) Flow cytometer analysis of CD4 and CD8 in ex vivo development of CD4−CD8− 
thymocytes from wild type or RORγt−/− mice for three days. Right panel is the frequency of 
total CD4+ thymocytes. (b) Flow cytometer analysis for RORγt expression by cells shown 
in a. (c) Flow cytometer analysis of ex vivo development of CD4−CD8−RORγt−/− 
thymocytes transduced with retrovirus expressing GFP only (EV), or together with RORγt 
or mutants incapable of binding DNA (RORγt-DBD) or co-activator (RORγt-AF2). Right 
panel is the percentage of CD4+ among 7-AAD− Thy1.2+GFP+ cells. (d) Flow cytometer 
analysis for IL-17A+ cells in naïve WT or RORγt−/− CD4+ T cells polarized under Th17 
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priming conditions for three days. Right panel is the percentage of IL-17A+ cells among 
CD4+ cells. (e) Flow cytometer analysis of IL-17A+ cells in RORγt−/− CD4+ T cells 
transduced with indicated retrovirus. Right panel is the percentage of IL-17A+ cells among 
CD4+GFP+ cells. (f) Flow cytometer analysis of ex vivo development of 
CD4−CD8−RORγt−/− thymocytes transdced with indicated retrovirus. Right panel is the 
quantification of the results. (g) Flow cytometer analysis of IL-17A+ cells in RORγt−/− 
CD4+ T cells transduced with indicated retrovirus. Right panel is the quantification of 
results. Data in right panel of a,c,d,e,f,g are mean ± s.e.m. **P < 0.01, ***P < 0.001 
(ANOVA test). Each symbol represents an individual experiment. Data are pooled from 
three experiments (right panel of a,c,d,e,f,g ), or are from one experiment representative of 
three experiments (b and left panel of a,c,d,e,f,g),
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Figure 2. S92 and L93 are critical for TH17 differentiation but not T cell development
(a) Schematic representation of RORγt structure and alanine-scanning mutants. Numbers 
indicate the positions of amino acids. DBD: DNA-binding domain. LBD: Ligand-binding 
domain. (b) Flow cytometer analysis of ex vivo thymocyte development (top panel) and 
TH17 differentiation of RORγt−/− cells retrovirally expressing indicated RORγt. (c) Top 
panel is the percentage of rescued thymocyte development (black/circles) and TH17 
differentiation (red/squares) by indicated RORγt mutants relative to WT RORγt (defined as 
100%). Bottom panel is the ratio of percentage of rescued thymocyte development to that of 
rescued Th17 differentiation. (d and e) Flow cytometer analysis of ex vivo thymocyte 
development (top panel) and TH17 differentiation of RORγt−/− cells retrovirally expressing 
indicated RORγt (f) Quantification of the results shown in d and e. Data in c,f are mean ± 
s.e.m. **P < 0.01, ***P < 0.001 (ANOVA test). Data are pooled from three experiments 
(c,f ), or are from one experiment representative of three experiments (b,d,e),
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Figure 3. RORγtM cannot induce genes critical for TH17 differentiation
(a) Heatmap visualization of the up-regulated (red) and down-regulated (green) genes 
determined by RNA-seq assay in RORγt−/− CD4+ T cells retrovirally reconstituted with EV, 
WT RORγt, or RORγtM and polarized under TH17 conditions for three days. (b) 
Comparison of gene expression profiles between RORγt−/− CD4+ T cells reconstituted with 
EV and RORγt (left panel), and between RORγt−/− CD4+ T cells reconstituted with 
RORγtM and RORγt (right panel). Colored dots represent selected critical TH17 genes as 
indicated. Average fragments per kilobase of transcript per million mapped reads (FRKM) 
values of three replicates are shown. (c) ChIP assay identified RORγt DNA-binding peaks in 
Il17a, Il17f, and Il23r loci. (d) ChIP analysis of RORγt interaction with Il17a (left) and Il23r 
(right) loci in RORγt−/− CD4+ T cells retrovirally expressing EV, WT RORγt, or RORγtM. 
Data are pooled from three experiments (a,b), or are from one experiment representative of 
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three experiments (c,d). Data in d are shown as mean ± s.e.m.; Each symbol represents an 
individual experiment. ** p<0.01 by ANOVA.
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Figure 4. RORγtM supports thymocyte development in vivo
(a) Thymic cellularity of indicated mice (n=5 per genotype). (b) Flow cytometer analysis of 
percentage of survival thymocytes stained with Annexin V and F-AAD after culturing for 
different times (n=3 per genotype). (c) Flow cytometer analysis of surface CD4 and CD8 in 
thymocytes. Right panel is the quantification of the percentage of indicated population of 
thymocytes (n=5 per genotype). (d) Flow cytometer analysis of CD24 and TCRβ expression 
for the maturity of CD8+ thymocytes. Right panel is the quantification of the percentage of 
indicated population of cells (n=5 per genotype). (e) Flow cytometer analysis of the forward 
scatter (FSC) in thymocytes of indicated mice. Right panel is the quantification of results 
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(n=5 per genotype). (F) Flow cytometer analysis of DNA content with 7-AAD in indicated 
thymocytes. Numbers indicate the percentage of cells with >2N of DNA. Right panel is the 
quantification of results (n=3 per genotype). (g) Comparison of gene expression profiles 
determined by RNA-seq between RORγt−/− and WT thymocytes (top panel) or between 
RORγtM and WT thymocytes (bottom panel). Colored dots indicate selected genes. Average 
fragments per kilobase of transcript per million mapped reads (FRKM) values of two 
replicates are shown. Data in b are mean ± s.e.m. Central line of box-whisker plot (a and 
right panel of c, d, e, f) represents median and whiskers indicate extreme data points. *P < 
0.05, **P < 0.01, NS non-significant (ANOVA test).Data are pooled from three experiments 
(h), are from one experiment representative of five experiments (left panel of c,d,e and f) or 
from one experiment representative of three experiments (g and left panel of f).
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Figure 5. RORγtM/M mice have defective TH17 differentiation
(a) Flow cytometer analysis of intracellular IFNγ or IL-17A in indicated naïve CD4+ T cells 
differentiated for three day under TH1 or TH17 priming conditions. Right panel is the 
quantification of the results (n=5 per genotype). (b) Flow cytometer analysis of RORγt 
expression in TH17 cells shown in a. (c) Mean EAE clinical score of indicated mice (female) 
different days after immunization with MOG35-55(n=10 for WT, n=8 for RORγt−/− and n=13 
for RORγt M/M). (d) Flow cytometer analysis of surface markers for different types of CNS 
infiltrated lymphocytes from indicated EAE-induced mice at the peak of disease. (e) qPCR 
analysis of expression of indicated cytokines in CNS-infiltrated lymphocytes of EAE-
induced mice. Data in e are mean ± s.e.m. Each symbol (e) represents an individual mouse. 
Central line of box-whisker plot (right panel of a, and d, e) represents median and whiskers 
indicate extreme data points. *P < 0.05, **P < 0.01, NS non-significant (ANOVA test).Data 
He et al. Page 23
Nat Immunol. Author manuscript; available in PMC 2018 February 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
are pooled from three experiments (c), or from one experiment representative of three 
experiments (b and left panel of a).
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Figure 6. RORγtM/M CD4+ T cells are defective in induction of EAE
(a) Mean EAE clinical score of Rag1−/− recipient mice (female) reconstituted with CD4+ 
cells from indicated mice at different days after immunization with MOG35-55 (n=5 per 
genotype). (b) Flow cytometer analysis of indicated surface markers for different types of 
CNS infiltrated lymphocytes in EAE-induced mice at the peak of disease. (c) qPCR analysis 
of expression of indicated cytokines in CNS-infiltrated lymphocytes of EAE-induced mice. 
(d) Flow cytometer analysis of intracellular IFNγ and GM-CSF in CNS-infiltrated CD4+ T 
cells from EAE-induced mice. (e, f) Percentage (e) and absolute number (f) of indicated 
CNS-infiltrated lymphocytes in EAE-induced mice. (g) Ratio of the expression of 
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pathogenic and nonpathogenic genes determined by qPCR between WT and RORγtM CD4+ 
T cells differentiated under regular Th17 priming conditions and pathogenic Th17 priming 
conditions (+IL-23) for three days (n=3 per genotype). (h) Ratio of the expression of 
pathogenic and nonpathogenic genes determined by qPCR between WT and RORγtMM 
CD4+ T cells obtained from EAE-induced mice (n=3 per genotype). Data c are mean ± 
s.e.m. **P < 0.01, NS non-significant (ANOVA test). Each symbol (c) represents an 
individual mouse. Central line of box-whisker plot (b, e and f) represents median and 
whiskers indicate extreme data points. Data are pooled from three experiments (a,b,c,e,f,g 
and h), or from one experiment representative of three experiments (d).
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Figure 7. RORγtM/M mice develop lymph nodes, but not Peyer’s patches
Cellularity of aorta, mesenteric, and inguinal lymph nodes and total number of Peyer’s 
patches in indicated mice (n=5 per genotype). Central line of box-whisker plot represents 
median and whiskers indicate extreme data points. **P < 0.01, NS non-significant (ANOVA 
test). Data are pooled from 5 mice.
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Figure 8. RORγtM interferes with the ubiquitination of RORγt at lysine 69
(a) Western blot analysis of RORγt in TUBE1-enriched ubiquitinated proteins from 
differentiated TH17 cells (left panel) or thymocytes (right panel). (b) Western blot analysis 
of ubiquitinated RORγt (Ub-RORγt) in HEK 293T cells expressing RORγt or RORγt-K69, 
together with HA-tagged ubiquitin for 48 hrs. (c) Western analysis of Ub-RORγt in HEK 
293T cells expressing RORγt-K69, together with HA-tagged WT or mutated ubiquitin. (d) 
Flow cytometer analysis of CD4 and CD8 in ex vivo development of thymocytes (top panel) 
or IL-17A+ cells in TH17 differentiation for three days in RORγt−/− thymocytes or CD4+ 
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cells retrovirally expressing indicated RORγt mutants. (e) Quantification of results shown in 
d. (f) qPCR analysis of mRNA levels of indicated genes in Th17 cells shown in e. (g) ChIP 
analysis of indicated RORγt binding to IL-17 promoter in RORγt−/− CD4+ T cells 
retrovirally expressing various RORγt and differentiated under TH17 priming conditions for 
three days. Hemoglobin gene (Hbb) locus is a control. Data in e,f,g are mean ± s.e.m. **P < 
0.01, NS non-significant (ANOVA test). Each symbol (f, g) represents an individual 
experiment. Data are pooled from three experiments (e, g), from five experiments (f), or 
from one experiment representative of three experiments (a,b,c and d). Full length gel 
imagines are available in supplementary figure 8.
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Table 1
Visualization of presence and absence of aorta, mesenteric, and inguinal lymph nodes in indicated mice (n=10 
per genotype). Data are pooled from 10 mice.
Mouse strain Aorta LN Messenteric LN Inguinal LN Peyer’s patches
WT + + + +
RORγt−/− − − − −
RORγtM/M + + + −
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